For adults with a BMI of 27+ or metabolic risk factors who want clinically proven weight loss that lasts — not another diet.
Start My Semaglutide Program View All ProgramsSemaglutide is a GLP-1 receptor agonist — it mimics the glucagon-like peptide-1 hormone your gut naturally produces after eating. By activating GLP-1 receptors in the brain, it reduces appetite, slows gastric emptying, and improves insulin sensitivity simultaneously.
The result is a reduction in caloric intake driven by genuine satiety — not willpower, not restriction. Clinical trials show average weight loss of 15–20% of body weight over 68 weeks, with significant metabolic improvements including reduced HbA1c, blood pressure, and cardiovascular risk markers.
Semaglutide is administered as a once-weekly subcutaneous injection. Dosing begins low (0.25mg) and escalates over 4–8 weeks to your maintenance dose (1–2.4mg), allowing your body to adjust and minimizing GI side effects.
Reduced appetite and initial satiety changes. Some patients experience mild nausea as the body adjusts. Most patients lose 2–4 pounds in the first month.
Appetite regulation becomes more consistent. Energy improves as metabolic function shifts. Average cumulative loss at 8 weeks: 5–8% of body weight.
Compounding metabolic benefits. Most patients report improved energy, blood sugar stability, and significant changes in body composition. Average loss at 12 weeks: 10–15% of body weight.
Our clinical team will review your health history and design a protocol built around your specific goals. Same-week consultations available.
Start My Semaglutide ProgramThe services provided have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before beginning any therapy program.